You Need a Job

And KP wants to help.

Tell you what.  Upload your job talk somewhere, or better yet convert it to a shareable G-Doc, and KinasePro will get you exposure by linking to it.  If you want more details on how this can work – email me.

AZD-7762

It’s going ph1, it’s from WO/2005/066163, and it’s been described.

Somebody send it to Ambit.  XL-844,  PF-477736, IC-83 are the known competition.

Takeda’s got…

a Jnk3 BMCL:

2ZDT and 2ZDU …reminds of 2R9S

R & D @ B I

With BIRB-796 a distant memory, BIBW-2992 in ph3 and given the new name Tovok, BIBF-1120 headed into ph3 and given the name Vargatef,  BI-2536 in multiple Ph2s, a new Ph1 Aurora inhibitor, and another backup PLK1 inhibitor undisclosed, but likely in-clinic or clinic-bound – what could possibly be next?

I can haz pyrimidines

PDK mod prolly from Berlex

Eck’s Got FAK

2JKQ, 2JKK, 2JKO, 2JKM,

Neat helix, & 2JKK is NVP TAE-226 but 2JKM (non-helix) is the closest thing to anything FAK in the clinic: PF-562271

Jnk Science

Roche Palo Alto just published 3E7O: JNK2 (7x mutant) bound to an indazole:

Which brings up that nearly two years ago I suggested CC-401 may be from an ’06 Celgene application.  Right flavor wrong compound, the drawn compound is CG-930 (IND filed Dec 18, 2007 – claimed in Ph1 for fibrotic diseases).  As NCI suggests CC-401 is an SP-600125 analog which incidentally is no longer on the CG pipeline.  

That’s life on the edge for yah.

PF-3814735

It’s Pfizer’s Ph1 Aurora inhibitor:

Who cares about the Roche p38 inhibitors?

Probably a few less people in PA then a few months ago, eh?  But this one’s been getting press recently:

WO/2008/104473

Best of KP

In case you came late to the party, here’s some of my favorites:

The Kinaverse

Approved Kinase Inhibitors

Ph3 Kinase inhibitors

S—-O

Cl—-O

Note the RSS feed of my reading list.

Also note comments are closed – email me if you’ve got something to say, or start your own blog.  Go on – Its fun.

AZ’s Bis-Morpholine

+ XRPD on multiple salt forms of this EphB4 inhibitor:

WO/2008/104754